Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.

Abstract

Data from the clinical absolute bioavailability (F) study with cobimetinib suggested that F was lower than predicted based on its low hepatic extraction and good absorption. The CYP3A4 transgenic (Tg) mouse model with differential expression of CYP3A4 in the liver (Cyp3a(-/-)Tg-3A4Hep) or intestine (Cyp3a(-/-)Tg-3A4Int) and both liver and intestine (Cyp3a… (More)
DOI: 10.1124/dmd.115.063743

Topics

2 Figures and Tables

Cite this paper

@article{Choo2015UseOT, title={Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.}, author={Edna F Choo and Sarah Woolsey and Kevin Dement and Justin Q. Ly and Kirsten Messick and Ann Ran-Ran Qin and Ryan H. Takahashi}, journal={Drug metabolism and disposition: the biological fate of chemicals}, year={2015}, volume={43 6}, pages={864-9} }